Calories and Cancer: The Role of Insulin-Like Growth Factor-1

  • Stephen D. HurstingEmail author
  • Sarah D. Smith
  • Alison E. Harvey
  • Laura M. Lashinger
Part of the Cancer Drug Discovery and Development book series (CDD&D)


The poem “On the Nature of Things,” written around 55 bc by Titus Lucretius Carus, is considered to be the first published statement about the potential impact of the overconsumption of food on risk of chronic diseases such as cancer (Lucretius 2008). This apparent connection between excess calorie intake and cancer began to develop into a working hypothesis in the mid-to-late 1800s, following the writings of John Hughes Bennett (1849) and William Lambe (1850). The first tests of the hypothesis that a calorie restriction (CR) dietary regimen can suppress tumors in animal models were reported in 1909 by Moreschi (1909) and extended by Sweet et al. in (1913) and Peyton Rous in (1914). These investigators showed that a low-calorie diet, relative to ad libitum (AL)-fed controls, inhibited the growth of transplanted tumors in mice. Intense interest in the comparison of CR versus AL-fed animals developed in the 1930s, when McCay and Crowell showed that reduced energy intake also increased lifespan in rodents (1934). CR research was further catalyzed by Tannenbaum et al., who consistently showed that the incidence of tumors in mice decreased when food intake was reduced (1944).


Epidermal Growth Factor Receptor Calorie Restriction Tuberous Sclerosis Complex Dwarf Mouse Epidermal Growth Factor Receptor Transactivation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Lucretius Carus, Titus. On the Nature of Things (Translated by A.E. Stallings). Penguin Press, NY, 2008.Google Scholar
  2. Bennett JH. On Cancerous and Canroid Growths. Sutherland and Knox, Edinburgh, 1849.Google Scholar
  3. Lambe W (with notes and additions by Shew, J.) Water and Vegetable Diet in Consumption, Scrofula, Cancer, Asthma and Other Chronic Diseases. Fowlers and Wells, NY, 1850.Google Scholar
  4. Moreschi C (1909) Beziehungen zwischen Ernahrung und Tumorwachstum. Zeitschrift fur Immunitatsforsch 2:661–675.Google Scholar
  5. Sweet JE, Carson-White EP, Saxon GJ. The relation of diets and of castration to the transmissible tumors of rats and mice. J Biol Chem 1913; 15:181–91.Google Scholar
  6. Rous P. The influence of diet on transplanted and spontaneous mouse tumors. J Exp Med 1914; 20:433–51.Google Scholar
  7. McCay CM, Crowell MF. 1934. Prolonging the life span. Sci. Mon. 39:405–14.Google Scholar
  8. Tannenbaum A. 1944. The dependence of the genesis of induced skin tumors on the caloric intake during different stages of carcinogenesis. Cancer Res. 4:673–79.Google Scholar
  9. Hursting, S.D., Lavigne, J.A., Berrigan, D., Perkins, S.N. and Barrett, J.C. (2003) Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med, 54:131–52.Google Scholar
  10. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN. Calorie restriction and Carcinogenesis: Lessons learned from 30 years of research. Carcinogenesis 2010; 31:83–9.Google Scholar
  11. Colman, R.J., Anderson, R.M., Johnson, S.C., Kastman, E.K., Kosmatka, K.J., Beasley, T.M., Allison, D.B., Cruzen, C., Simmons, H.A., Kemnitz, J.W. and Weindruch, R. (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science, 325, 201–4.Google Scholar
  12. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010 303:235–41.Google Scholar
  13. Ogden CL, Fryar CD, Carroll MD, Flegal KM. Mean body weight, height, and body mass index, United States 1960–2002. Advance data from vital and health statistics; no 347. Hyattsville, Maryland: National Center for Health Statistics. 2004.Google Scholar
  14. Calle, E.E., Rodriguez, C., Walker-Thurmond, K. and Thun, M.J. (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 348, 1625–38.Google Scholar
  15. Hursting SD, Lashinger LM, Wheatley KW, Rogers CJ, Colbert LH, Nunez, NP, Perkins SN. Reducing the weight of cancer: Mechanistic targets for breaking the obesity-carcinogenesis link. Best Pract Res Clin Endocrinol Metab, 2008, 22:659–669.Google Scholar
  16. Yakar, S., Leroith, D. and Brodt, P. (2005) The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev, 16, 407–20.Google Scholar
  17. Sara, V.R. and Hall, K. (1990) Insulin-like growth factors and their binding proteins. Physiol Rev, 70, 591–614.Google Scholar
  18. Ma QL, Tang TL, Yin JY, Peng ZY, Yu M, Liu ZQ, Chen FP. Role of insulin-like growth factor-1 in regulating cell cycle progression. Biochem Biophys Res Comm 2009; 389:150–5.Google Scholar
  19. LeRoith, D., Baserga, R., Helman, L. and Roberts, C.T., Jr. (1995) Insulin-like growth factors and cancer. Ann Intern Med, 122, 54–9.Google Scholar
  20. Resnicoff, M., Abraham, D., Yutanawiboonchai, W., Rotman, H.L., Kajstura, J., Rubin, R., Zoltick, P. and Baserga, R. (1995) The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res, 55, 2463–9.Google Scholar
  21. Pollak, M. (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915–28.Google Scholar
  22. Rogers CJ, Colbert LH, Berrigan D, Greiner JW, Perkins SN, Hursting SD. Physical activity and cancer prevention: Pathways and targets for intervention. Sports Medicine 2008; 38(4): 221–57.Google Scholar
  23. McTiernan A, Sorensen B, Yasui Y, Tworoger SS, Ulrich CM, Irwin ML, Rudolph RE, Stanczyk FZ, Schwartz RS, Potter JD. No effect of exercise on insulin-like growth factor-1 and ­insulin-like binding protein 3 in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiol Biomarkers Prev 14:1020, 2005.Google Scholar
  24. Koistinen H, Koistinen R, et al. Effect of marathon run on serum IGF-1 and IGF-binding protein 1 and 3 levels. J Appl Physiol 1996; 80(3): 760–4.Google Scholar
  25. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17:328–36.Google Scholar
  26. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor, IGF binding proteins, their biologic interactions, and colorectal cancer. JNCI 2002; 94:972–80.Google Scholar
  27. Luo, J., Manning, B. D., and Cantley, L. C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell, 4: 257–62, 2003.Google Scholar
  28. Engelman, J. A., Luo, J., and Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet, 7: 606–19, 2006.Google Scholar
  29. Shaw, R. J., and Cantley, L. C. Ras, PI(3)K and mTOR signaling controls tumor cell growth. Nature, 441: 424–30, 2006.Google Scholar
  30. Brazil, D. P., Yang, Z. Z., and Hemmings, B. A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci, 29: 233–42, 2004.Google Scholar
  31. Dillon RL, Muller WJ. Distinct biological roles for the AKt family in mammary tumor progression. Cancer Res 2010; 70:426064.Google Scholar
  32. Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 8: 179–83, 2005.Google Scholar
  33. Sarbassov DD, Sabatini DM. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem 2005; 280: 39505–39509.Google Scholar
  34. Guertin, D.A. and D.M. Sabatini, An expanding role for mTOR in cancer. Trends Mol Med, 2005. 11(8): p. 353–61.Google Scholar
  35. Kwiatkowki DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genetics 2005; 14:R251-8.Google Scholar
  36. Moore T, Beltran L, Carbijal S, Strom S, Traag J, Hursting SD, DiGiovanni J, Dietary energy balance modulates signaling through the Akt/mTOR pathway in multiple tissues. Cancer Prev Res 2008; 1:65–76.Google Scholar
  37. Jiang, W., Z. Zhu, Thompson H. Dietary energy restriction modulates the activity of amp-activated protein kinase, akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. cancer research, 2008. 68: p. 5492–5499.Google Scholar
  38. Moore T, Carbijal S., Beltran L, Perkins SN, Hursting SD, DiGiovanni J, Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating IGF-1 levels. Cancer Res, 2008. 68: p. 3680–8.Google Scholar
  39. The Endogenous Hormones and Breast Cancer Collaborative Group. Insulin-like growth factor-q (IGF1), IGF binding protein 3 (IGFBP3) and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncology 11:530–42, 2010.Google Scholar
  40. Chan JM, Stampfer MJ, Giovannucci E, et al. 1998. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563–66.Google Scholar
  41. Wolk A, Mantzoros CS, Andersson SO, et al. 1998. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 90:911–15.Google Scholar
  42. Yu H, Spitz MR, Mistry J, et al. 1999. Plasma levels of insulin-like growth factor--I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst. 91:151–56.Google Scholar
  43. Ma J, Pollak MN, Giovannucci E, et al. 1999. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 91:620–25.Google Scholar
  44. Giovannucci E, Pollak MN, Platz EA, et al. 2000. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol. Biomarkers Prev. 9:345–49.Google Scholar
  45. Petridou E, Dessypris N, Spanos E, et al. 1999. Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia. Int. J. Cancer 80:494–96.Google Scholar
  46. Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon R. Serum IGF-1, IGF-II, IGFBP-3 and IGF-1/BP-3 molar ratio and risk of pancreatic cnacer in the PLCO cancer screening trial. Cancer Epidemiol Biomarkers Prev 2010; 19:2298–306.Google Scholar
  47. Macaulay, V.M. (1992) Insulin-like growth factors and cancer. Br J Cancer, 65, 311–20.Google Scholar
  48. Flurkey K, Papaconstantinou J, Miller RA, Harrison DE. 2001. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc. Natl. Acad. Sci. USA 98:6736–41.Google Scholar
  49. Bartke A, Brown-Borg HM. Life extension in the dwarf mouse. Curr Topics Dev Biol 2004; 63:189–225.Google Scholar
  50. Anisimov VN. 2001. Mutant and genetically modified mice as models for studying the relationship between aging and carcinogenesis. Mech. Ageing Dev. 122:1221–55.Google Scholar
  51. DiGiovanni J, Bol DK, Wilker E, et al. 2000. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Res. 60:1561–70.Google Scholar
  52. Hursting SD, Perkins SN, Lavigne JA, Beltran L, Haines DC, Hill HL, Alvord WG, Barrett JC, DiGiovanni J. Urothelial overexpression of insulin-like growth factor-1 increases susceptibility to p-Cresidine-induced bladder carcinogenesis in transgenic mice. Mol Carcinogenesis 2009; 48:671–7.Google Scholar
  53. Yiping Wu, Karen Cui, Keiko Miyoshi, Lothar Hennighausen, Jeffrey E. Green, Jennifer Setser, Derek LeRoith, Shoshana Yakar. Reduced Circulating Insulin-like Growth Factor I Levels Delay the Onset of Chemically and Genetically Induced Mammary Tumors. Cancer Res 2003; 63:4384–88.Google Scholar
  54. Olivo-Marston S, Hursting SD, Lavigne J, Perkins SN, Marouf R, Yakar S, Harris CC. Genetic reduction of insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Mol Carcinogenesis 2009, 48:1071–6.Google Scholar
  55. Lashinger LM, Malone LM, McArthur MJ, Goldberg JA, Daniels EA, Pavone A, Colby JK, Perkins SN, Fischer SM, Hursting SD. Genetic reduction of insulin-like growth factor-1 mimics the anticancer effects of calorie restriction on cyclooxygenase-2-drive pancreatic cancer. Cancer Prev Res 2010; in press.Google Scholar
  56. Polunovsky V and Houghton PJ (2010). mTOR pathway and mTOR inhibitors in cancer therapy. New York, NY: Humana Press.Google Scholar
  57. Wu Y, Brodt P, Sun H, Mejia W, Novosyadlyy R, Nunez N, Chen X, Mendoza A, Hong SH, Khanna C, Yakar S. Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis Cancer Res 70: 57–67, 2010.Google Scholar
  58. Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13: 423–9.Google Scholar
  59. Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, and Sarcevic B. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 2005; 229(1–2): 161–73.Google Scholar
  60. Sachdev D and Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001; 8(3):197–209.Google Scholar
  61. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O’Regan RM, and Sharma D. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 2008; 68(23): 9712–22.Google Scholar
  62. Ozbay T and Nahta R. A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells. Mol Cancer Res 2008; 6(6): 1052–8.Google Scholar
  63. Balañá ME, Labriola L, Salatino M, Movsichoff F, Peters G, Charreau EH, and Elizalde PV. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 2001; 20(1): 34–47.Google Scholar
  64. Shida D, Kitayama J, Mori K, Watanabe T and Nagawa H. Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Res 2005; 65(20): 9159–63.Google Scholar
  65. Hursting SD, Lashinger LM, Colbert LH, Rogers CJ, Wheatley KW, Nunez NP, Mahabir S, Barrett JC, Forman MR, and Perkins SN. Energy balance and carcinogenesis: underlying pathways and targets for intervention. Curr Cancer Drug Targets 2007; 7(5): 484–91.Google Scholar
  66. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, and Anderson KC. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21(37): 5673–83.Google Scholar
  67. Fenton JI, Birmingham JM, Hursting SD, and Hord NG. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. Int J Cancer 2008; 122(11): 2437–45.Google Scholar
  68. Fang J, Zhou Q, Shi XL, Jiang BH. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis 2007; 28(3): 713–23.Google Scholar
  69. Garafalo C and Surmacz E. Leptin and cancer. Cell Phys 2005; 207:12–22.Google Scholar
  70. Sachdev D and Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Therap 2007; 6:1–12.Google Scholar
  71. Eng-Wong J, Hursting SD, Perkins SN, Zujewski J. Effects of raloxifene on insulin-like growth factor (IGF)-1, IGF-binding protein-3 and leptin in premenopausal women at high risk for breast cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:1468–73.Google Scholar
  72. Lubet RA, Christov K, Nunez N, Hursting SD, Steele VE, Juliana MM, Eto I, Grubbs CJ. Effects of the RXR agonist targretin in the methylnitrosourea-induced mammary cancer model: Dose response curves, cancer cell proliferation and apoptosis, and serum IGF-1 levels. Carcinogenesis 2005; 26:441–8.Google Scholar
  73. DeAngel RD, Smith SD, Perkins SN, Glickman R, Hursting SD. Anti-tumor effects of ursolic acid in a mouse model of postmenopausal breast cancer. Nutr Cancer 2010; in press.Google Scholar
  74. Fang J. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis 2006; 28:713–23.Google Scholar
  75. Anand P, Sundaram C, et al. Curcumin and Cancer: an “old-age” disease with an “age-old” solution. Cancer Letters 2008; 267(1): 133–64.Google Scholar
  76. Harrison, D.E., Strong, R., Sharp, Z.D., Nelson, J.F., Astle, C.M., Flurkey, K., Nadon, N.L., Wilkinson, J.E., Frenkel, K., Carter, C.S., Pahor, M., Javors, M.A., Fernandez, E. and Miller, R.A. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460, 392–5.Google Scholar
  77. Sahra IB, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease in cyclin D1 levels. Oncogene 2008; 27:3576–3586.Google Scholar
  78. Hardie DG. AMPK: A key regulator of energy balance in the single cell and the whole organism. Int J Obes 2008; 32:S7–12.Google Scholar
  79. Memmott RM, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prevention Res 2010; 3:1066–76.Google Scholar
  80. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620–5. PMCID: 2732153.Google Scholar
  81. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137(2):482–8.Google Scholar
  82. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297–302.Google Scholar
  83. Hosono et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prevention Res 2010; 3:1077–83.Google Scholar
  84. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res 2010; 3:1060–65.Google Scholar
  85. Firestein, R., Blander, G., Michan, S., Oberdoerffer, P., Ogino, S., Campbell, J., Bhimavarapu, A., Luikenhuis, S., de Cabo, R., Fuchs, C., Hahn, W.C., Guarente, L.P. and Sinclair, D.A. (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One, 3, e2020.S.Google Scholar
  86. Signorelli, P. and Ghidoni, R. (2005) Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem, 16, 449–66.Google Scholar
  87. Liu, T., Liu, P.Y. and Marshall, G.M. (2009) The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res, 69, 1702–5.Google Scholar
  88. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009; 458:725–31.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Stephen D. Hursting
    • 1
    • 2
    Email author
  • Sarah D. Smith
    • 1
  • Alison E. Harvey
    • 1
  • Laura M. Lashinger
    • 1
  1. 1.Department of Nutritional SciencesThe University of Texas at AustinAustinUSA
  2. 2.Department of CarcinogenesisThe University of Texas MD Anderson Cancer CenterSmithvilleUSA

Personalised recommendations